A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma

F. Morschhauser, C. Recher, N. Milpied, R. Gressin, G. Salles, P. Brice, N. Vey, C. Haioun, P. Colombat, J.F. Rossi, E. Deconinck, F. Lazreg, L. Bergougnoux, G. Delsol, M. Attal

Open source

DOI: 10.1093/annonc/mds202
Published: 2012-10
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/annonc/mds202,
  title = {A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma},
  author = {F. Morschhauser and C. Recher and N. Milpied and R. Gressin and G. Salles and P. Brice and N. Vey and C. Haioun and P. Colombat and J.F. Rossi and E. Deconinck and F. Lazreg and L. Bergougnoux and G. Delsol and M. Attal},
  year = {2012},
  journal = {Annals of Oncology},
  doi = {10.1093/annonc/mds202},
  url = {https://doi.org/10.1093/annonc/mds202}
}

RIS

TY  - JOUR
TI  - A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma
AU  - F. Morschhauser
AU  - C. Recher
AU  - N. Milpied
AU  - R. Gressin
AU  - G. Salles
AU  - P. Brice
AU  - N. Vey
AU  - C. Haioun
AU  - P. Colombat
AU  - J.F. Rossi
AU  - E. Deconinck
AU  - F. Lazreg
AU  - L. Bergougnoux
AU  - G. Delsol
AU  - M. Attal
PY  - 2012
JO  - Annals of Oncology
DO  - 10.1093/annonc/mds202
UR  - https://doi.org/10.1093/annonc/mds202
ER  -

APA

Morschhauser, F., Recher, C., Milpied, N., Gressin, R., Salles, G., Brice, P., Vey, N., Haioun, C., Colombat, P., Rossi, J., Deconinck, E., Lazreg, F., Bergougnoux, L., Delsol, G., & Attal, M. (2012). A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. Annals of Oncology. https://doi.org/10.1093/annonc/mds202

Source records

crossref · retrieved 2026-09-27T13:35:48.797Z